Measured by the ability of the immobilized protein to support the adhesion of U937 human histiocytic lymphoma cells. When cells are added to VCAM1 coated plates (10 μg/mL, 100 μL/well) approximately > 70% cells will adhere after 1 hour of incubation at 37℃.

VCAM-1 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 100.8 kDa and the accession number is P19320-1.

Human

HEK293 Cells

VCAM-1,vascular cell adhesion molecule 1,INCAM-100,CD106

A DNA sequence encoding the extracellular domain (Met 1-Pro 697) of human VCAM1 (NP_001069.1) was expressed with the Fc region of human IgG1 at the C-terminus. Predicted N terminal: Phe 25

≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC.

Reconstituted with sterile deionized water to 0.25 mg/mL. Reconstitution conditions may vary depending on the lot.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy